At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
REGN Regeneron Pharmaceuticals
Not Yet Opened 10-27 16:00:00 EDT
816.10
+8.43
+1.04%
盘后815.03
-1.07-0.13%
19:45 EDT
High816.14Low804.05Vol726.15K
Open807.67D1 Closing807.67Amplitude1.50%
Mkt Cap84.02BTradable Cap80.70BTotal Shares102.95M
T/O589.93MT/O Rate0.73%Tradable Shares98.88M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Regeneron Pharmaceuticals this quarter’s revenue is expected to increase by 26.61%, and institutional views are predominantly bullish
Earnings Agent  ·  10-23
Earning Preview: Regeneron Pharmaceuticals this quarter’s revenue is expected to increase by 26.61%, and institutional views are predominantly bullish
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  04:41
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day
Regeneron Secures $270M U.S. Contract Extension for Ebola Treatment Inmazeb
Dow Jones  ·  10-26 19:35
Regeneron Secures $270M U.S. Contract Extension for Ebola Treatment Inmazeb
Regeneron Extends BARDA Ebola Treatment Supply Deal, Adding About $270 Million
Reuters  ·  10-26 19:08
Regeneron Extends BARDA Ebola Treatment Supply Deal, Adding About $270 Million
Regeneron Pharmaceuticals - Extends Barda Agreement to Provide Additional Inmazeb Supply for U.S. Ebola Preparedness
THOMSON REUTERS  ·  10-26 19:00
Regeneron Pharmaceuticals - Extends Barda Agreement to Provide Additional Inmazeb Supply for U.S. Ebola Preparedness
Regeneron Pharmaceuticals - to Deliver Additional Inmazeb Doses to U.S. Government Through 2031 for $270 Mln
THOMSON REUTERS  ·  10-26 19:00
Regeneron Pharmaceuticals - to Deliver Additional Inmazeb Doses to U.S. Government Through 2031 for $270 Mln
Regeneron announces longer-term data for Phase 2 C-POST trial of Libtayo
TIPRANKS  ·  10-26 05:00
Regeneron announces longer-term data for Phase 2 C-POST trial of Libtayo
What Regeneron Pharmaceuticals Buyers Were Betting On
Simply Wall St.  ·  10-25 17:37
What Regeneron Pharmaceuticals Buyers Were Betting On
Regeneron Pharmaceuticals - Libtayo Achieves 37% Reduction in Risk of Death at 44 Months (Hr: 0.63)
THOMSON REUTERS  ·  10-25 17:16
Regeneron Pharmaceuticals - Libtayo Achieves 37% Reduction in Risk of Death at 44 Months (Hr: 0.63)
Regeneron Pharmaceuticals - Libtayo Confirms Sustained Disease-Free Survival Benefit Including Mrd Negative Patients
THOMSON REUTERS  ·  10-25 17:16
Regeneron Pharmaceuticals - Libtayo Confirms Sustained Disease-Free Survival Benefit Including Mrd Negative Patients
Regeneron's Libtayo Cuts Death Risk 37% in High-Risk Skin Cancer Trial Follow-up
Reuters  ·  10-25 17:15
Regeneron's Libtayo Cuts Death Risk 37% in High-Risk Skin Cancer Trial Follow-up
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
GlobeNewswire  ·  10-25 17:15
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
A 42% Risk Reduction—and an 18% Stock Drop
Bellwether Stocks Movement  ·  10-24
A 42% Risk Reduction—and an 18% Stock Drop
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses on the Day
Dow Jones  ·  10-24
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses on the Day
Regeneron Pharmaceuticals (REGN) Pushes Ahead In Weight Loss With Two Distinct Drug Bets
Simply Wall St.  ·  10-23
Regeneron Pharmaceuticals (REGN) Pushes Ahead In Weight Loss With Two Distinct Drug Bets
Regeneron Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains
Dow Jones  ·  10-23
Regeneron Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains
Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850
MT Newswires Live  ·  10-22
Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $980 From $960
MT Newswires Live  ·  10-21
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $980 From $960
Regeneron Pharmaceuticals, Inc. : TD Cowen Raises Target Price to $980 from $960
THOMSON REUTERS  ·  10-21
Regeneron Pharmaceuticals, Inc. : TD Cowen Raises Target Price to $980 from $960
Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains
Dow Jones  ·  10-21
Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Introduction

Company Name.
Regeneron Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Issue price:
--